ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Inclusion Criteria: * Adult patient, \>/= 18 years of age, \</= 70 years of age. * HER2-positive breast cancer * Histologically confirmed invasive breast carcinoma * Clinical stage T2-4/N0-3/M0 or node positive at presentation (patients with T1 tumors will not be eligible) * Known hormone-receptor status * Non previous anti-breast cancer neoadjuvant chemotherapy * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Adequate hematologic, renal and liver function * Screening Left ventricular ejection fraction (LVEF) \>/= 50% on echocardiogram (ECHO) * Adequate organ function Exclusion Criteria: * Stage IV (metastatic) breast cancer or bilateral breast cancer * History of any prior (ipsi- or contralateral breast cancer except lobular carcinoma in situ) * History of other malignancy within the last 5 years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other non-breast malignancies with a similar outcome to those mentioned above * Cardiopulmonary dysfunction as defined by protocol * Current severe, uncontrolled systemic disease * Pregnant or lactating women * Any known active liver disease, e.g. due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis * Concurrent serious uncontrolled infections requiring treatment or known infection with HIV * History of intolerance, including Grade 3 to 4 infusion reaction or * hypersensitivity to trastuzumab or chemotherapy drugs